HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.

AuthorsXiaoxia Hu, Jiaxiang Liu, Chenguang Bai, Jianmin Wang, Xianmin Song
JournalEuropean journal of haematology (Eur J Haematol) Vol. 89 Issue 2 Pg. 183-4 (Aug 2012) ISSN: 1600-0609 [Electronic] England
PMID22571229 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Hormonal
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Dexamethasone
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Antineoplastic Agents, Hormonal (administration & dosage)
  • Boronic Acids (administration & dosage)
  • Bortezomib
  • Dexamethasone (administration & dosage)
  • Female
  • Histiocytosis (drug therapy, etiology, pathology)
  • Humans
  • Paraproteinemias (complications, drug therapy, pathology)
  • Pyrazines (administration & dosage)
  • Thalidomide (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: